Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported.
Sanofi sees continued growth and strong financials despite a pipeline setback. Click for this updated look at SNY stock ...
COVID-19, RSV, and influenza immunizations show continued safety and substantial effectiveness against hospitalization across various populations.
UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback